Kymab is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.

Biotechnology

Kymab

Simon Sturge

Richard Williams

David Melvin

Anne Hyland

Jasper Clube

Allan Bradley

Nigel Clark

Research and Development Team

Advisory Team

Leadership Team

Non-Executive Governance Team

Operations Team

Support and Administrative

Teams at Kymab